替尔泊肽对比赖脯胰岛素联合基础胰岛素治疗2型糖尿病:SURPASS-6随机临床试验
SURPASS-6是一项开放标签3b期试验,在1428例基础胰岛素控制不佳的2型糖尿病患者中比较每周替尔泊肽与每日三次赖脯胰岛素联合甘精胰岛素的效果。第52周时,替尔泊肽组HbA1c降幅和体重降幅均优于赖脯胰岛素组,达到HbA1c<7.0%的比例更高,低血糖事件率更低。
要点
- 替尔泊肽组第52周HbA1c降幅-2.1% vs 赖脯胰岛素组-1.1%,估计治疗差异-0.98%(95%CI -1.17%至-0.79%),达到非劣效和统计学优效。
- 替尔泊肽组体重变化-9.0 kg vs 赖脯胰岛素组+3.2 kg,估计治疗差异-12.2 kg(95%CI -13.4至-10.9)。
- 替尔泊肽组达到HbA1c<7.0%的比例68% vs 赖脯胰岛素组36%(OR 4.2,95%CI 3.2-5.5);低血糖事件率0.4 vs 4.4事件/患者年。
核心结论
- 在基础胰岛素控制不佳的2型糖尿病患者中,每周替尔泊肽对比餐时胰岛素作为甘精胰岛素的附加治疗,可降低HbA1c和体重,且低血糖更少。
研究设计与样本
- 开放标签3b期随机临床试验,在15个国家135个中心开展,参与者入组时间为2020年10月19日至2022年11月1日。
- 共纳入1428例接受基础胰岛素的成人2型糖尿病患者,按1:1:1:3随机分配至替尔泊肽5 mg(n=243)、10 mg(n=238)、15 mg(n=236)或每日三次赖脯胰岛素(n=708)。
- 主要结局为第52周HbA1c自基线变化,替尔泊肽汇总队列对比赖脯胰岛素非劣效性界值0.3%。
主要发现
- 1428例随机参与者中女性824例(57.7%),平均(SD)年龄58.8(9.7)岁,平均(SD)HbA1c 8.8%(1.0%),1304例(91.3%)完成试验。
- 第52周替尔泊肽汇总队列HbA1c估计平均变化-2.1% vs 赖脯胰岛素-1.1%,平均HbA1c水平6.7% vs 7.7%,估计治疗差异-0.98%(95%CI -1.17%至-0.79%),P<.001,达到非劣效和统计学优效。
- 替尔泊肽组体重估计平均变化-9.0 kg vs 赖脯胰岛素组3.2 kg,估计治疗差异-12.2 kg(95%CI -13.4至-10.9)。
- 达到HbA1c<7.0%的比例替尔泊肽组68%(483/716)vs 赖脯胰岛素组36%(256/708),OR 4.2(95%CI 3.2-5.5)。
- 替尔泊肽最常见不良事件为轻至中度胃肠道症状(恶心14%-26%;腹泻11%-15%;呕吐5%-13%);低血糖事件率(血糖<54 mg/dL或严重低血糖)替尔泊肽汇总组0.4事件/患者年 vs 赖脯胰岛素组4.4事件/患者年。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Tirzepatide is a glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 receptor agonist used for the treatment of type 2 diabetes. Efficacy and safety of adding tirzepatide vs prandial insulin to treatment in patients with inadequate glycemic control with basal insulin have not been described. OBJECTIVE: To assess the efficacy and safety of tirzepatide vs insulin lispro as an adjunctive therapy to insulin glargine. DESIGN, SETTING, AND PARTICIPANTS: This open-label, phase 3b clinical trial was conducted at 135 sites in 15 countries (participants enrolled from October 19, 2020, to November 1, 2022) in 1428 adults with type 2 diabetes taking basal insulin. INTERVENTIONS: Participants were randomized (in a 1:1:1:3 ratio) to receive once-weekly subcutaneous injections of tirzepatide (5 mg [n = 243], 10 mg [n = 238], or 15 mg [n = 236]) or prandial thrice-daily insulin lispro (n = 708). MAIN OUTCOMES AND MEASURES: Outcomes included noninferiority of tirzepatide (pooled cohort) vs insulin lispro, both in addition to insulin glargine, in HbA1c change from baseline at week 52 (noninferiority margin, 0.3%). Key secondary end points included change in body weight and percentage of participants achieving hemoglobin A1c (HbA1c) target of less than 7.0%. RESULTS: Among 1428 randomized participants (824 [57.7%] women; mean [SD] age, 58.8 [9.7] years; mean [SD] HbA1c, 8.8% [1.0%]), 1304 (91.3%) completed the trial. At week 52, estimated mean change from baseline in HbA1c with tirzepatide (pooled cohort) was -2.1% vs -1.1% with insulin lispro, resulting in mean HbA1c levels of 6.7% vs 7.7% (estimated treatment difference, -0.98% [95% CI, -1.17% to -0.79%]; P < .001); results met noninferiority criteria and statistical superiority was achieved. Estimated mean change from baseline in body weight was -9.0 kg with tirzepatide and 3.2 kg with insulin lispro (estimated treatment difference, -12.2 kg [95% CI, -13.4 to -10.9]). The percentage of participants reaching HbA1c less than 7.0% was 68% (483 of 716) with tirzepatide and 36% (256 of 708) with insulin lispro (odds ratio, 4.2 [95% CI, 3.2-5.5]). The most common adverse events with tirzepatide were mild to moderate gastrointestinal symptoms (nausea: 14%-26%; diarrhea: 11%-15%; vomiting: 5%-13%). Hypoglycemia event rates (blood glucose level <54 mg/dL or severe hypoglycemia) were 0.4 events per patient-year with tirzepatide (pooled) and 4.4 events per patient-year with insulin lispro. CONCLUSIONS AND RELEVANCE: In people with inadequately controlled type 2 diabetes treated with basal insulin, weekly tirzepatide compared with prandial insulin as an additional treatment with insulin glargine demonstrated reductions in HbA1c and body weight with less hypoglycemia. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT04537923.
引用
- Rosenstock J, Frías JP, Rodbard HW, et al. Tirzepatide vs Insulin Lispro Added to Basal Insulin in Type 2 Diabetes: The SURPASS-6 Randomized Clinical Trial. JAMA. 2023. PMID: 37786396. doi:10.1001/jama.2023.20294
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。